Our goals in biotechnology are straightforward. We invest in novel science, and we seek breakthroughs – truly innovative medicines and platform technologies, and diagnostics that address critical, unmet medical needs, and that have the potential to change the practice of medicine.
We empower entrepreneurs – with capital, but also with insight based on our extensive industry experience, and with access to the executive talent and pharmaceutical companies in our professional network. Our investment team also has an extensive record of forming and growing companies. Our proprietary capabilities include in-house incubation and company creation. Our portfolio companies benefit from our venture partners – veteran entrepreneurs who work exclusively with us.
We make initial investments at levels from seed capital through early clinical development stages. And many of those investments have made a difference to patients. We have an unparalleled track record and a long history of bringing drugs from discovery, through development, and into the market. Our investment in early-stage companies has led to the identification of several new classes of drugs which have now become multibillion-dollar categories, including VGEF inhibitors (now generating over $11 billion in annual sales) and PARP inhibitors, projected to be a multibillion dollar drug category. We have supported the development of over a dozen drugs in such categories as oncology, neuroscience and infectious disease – drugs that have changed lives.
We are located where the action is. Our transatlantic biotech group is based in our offices in Boston, San Francisco and London, the top three centers of biotech innovation.
Dementia Discovery Fund
SV won the mandate to manage the Dementia Discovery Fund in August 2015 against competition from more than fifteen other specialist healthcare venture capital firms.
Adimab, LLC has developed a fully integrated platform for antibody discovery and manufacturing which offers customers/ acquirers a very rapid, 2-3 month path from target to optimized antibody while eliminating most, if not all, third party royalties.Visit website
Alba based in Baltimore, MD, is focused on the development and commercialization of pharmaceuticals for the treatment of inflammatory and immune mediated diseases. Alba's technology provides the ability to transiently open or close internal barriers such as the intestinal mucosa. Alba is applying its technology to develop treatments for celiac disease and other autoimmune conditions.Visit website
Dedicated to developing and commercializing pharmaceuticals for the treatment of diabetes and related metabolic disorders.
Archemix, based in Cambridge, MA, is developing nucleic acid aptamers for therapeutic indications, building on a broad IP portfolio acquired from Gilead/Nexstar.Visit website
Development of Monoclonal Antibodies to target infectious diseases.Visit website
Artios Pharma Ltd was established in May 2016 to build an innovative DNA Damage Response (DDR) target pipeline with the potential to transform cancer therapy.Visit website
Focused on preclinical exploration and development of potential treatments for people with hearing disorders, including noise-induced hearing loss or tinnitus.Visit website
Avitide provides an industry-leading custom affinity purification discovery service. The Avitide platform discovers and optimizes selective affinity ligands specific towards customer’s targets for use as bioprocess purification resins in a matter of 4-6 weeks. Avitide’s proprietary affinity ligands are implemented across an array of industry-accepted resins for selective and scalable chromatographic separations.Visit website
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing transformative, life-changing therapies that have the potential to transform patients’ lives in a single dose. The Company is focused on the development of its Phase 1 programs in Fabry disease and acute myeloid leukemia (AML), while actively building a pipeline of therapies to treat other rare diseases, and solid and liquid cancers.Visit website
Developing a platform technology that may enable the creation of a new generation of biotherapeutics.Visit website
Spin out from GSK. Focused on the development of novel analgesics with commercially attractive efficacy, responder-rate and side effect profiles
Good Start Genetics, Inc
A molecular diagnostics company focused on genetic screening of inherited disorders, by harnessing a next generation sequencing platform to provide clinicians and patients with the highest carrier detection rates possible.Visit website
Will leverage novel insights into the expression of human endogenous retroviruses in different cancers to develop a pipeline of first-in-class cancer vaccines.
Kesios Therapeutics Limited
Developed novel therapeutics for the treatment of multiple myeloma and other cancers.
Sitryx Therapeutics Limited
Will leverage metabolic insights into the fumarate/fumarate hydratase (F/FH) drug target/pathway to develop a pipeline of first-in-class small molecule drugs to treat a broad range of orphan and blockbuster indications, starting with cancer.
Sutro Biopharma, Inc.
Sutro Biopharma's mission is to enable the production of low-cost, high quality rapidly developed protein pharmaceuticals and innovative vaccines that cannot be manufactured by existing technologies. Previously known as Fundamental Applied Biology's (FAB).Visit website
(NASDAQ: ACHN). Achillion, based in New Haven, CT, is focused on the discovery, development and commercialization of innovative small molecule therapeutics for the treatment and/or prevention of serious infections associated with drug resistant viruses or bacteria.Visit website
Aderis Pharmaceuticals was a Cardiovascular, renal and neurological disease focused therapeutics company dedicated to making a significant difference to people living with cardiovascular, renal and neurological diseases.
Affibody is a biotech company that uses unique affinity ligands to develop products for molecular imaging, targeted therapy and biotechnology applications. The lead product is a Her2 affibody for clinical imaging in breast cancer, and its pipeline includes other oncology imaging affibodies. In addition, affibodies are sold as research reagents and for use in protein separations.Visit website
Affinium Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines stemming from the bacterial fatty acid synthesis pathway.
Allocure is a biotechnology company at the forefront of innovative cell therapies for the treatment of Acute Renal Failure (ARF).
Allos Therapeutics was developing and commercializing innovative small molecule therapeutics for the treatment of cancer.
Antiva (Vantia Spin-Out)
Spin-Out of Vantia Therapeutics.
Avant Immunotherapeutics, Inc.
Avera focused on the development of small molecule drugs for the treatment of diseases affecting the central nervous system (CNS). Key programs are Alzheimer's disease, schizophrenia associated cognition deficits, IBS, and OAB, and developing an ultra-short acting anaesthesia compound.
Axys developed a protease-inhibitor based products for cancer & inflammatory diseases.
Celldex merged with the quoted company Avant Immunotherapeutics (ticker:'AVAN') in March 2008. Celldex, formerly a wholly owned subsidiary of Medarex Inc., merged with Lorantis Ltd in 2005. Celldex pursues immunological approaches to the treatment of cancers, infectious disease and immunological disorders.Visit website
Cellzome is a drug discovery company building a R&D pipeline in chronic diseases by leveraging its unique drug proteomics engine. The business is based in Heidelberg, Germany and Cambridge, UK.
Cognis is a global supplier of innovative speciality chemicals for the cosmetics, detergents and cleaners industries and nutrional ingredients to the food and healthcare markets.
Dynogen is a neuroscience-based company focused on genito-urinary (GU) and gastro-intestinal (GI) disorders. The company is using its knowledge of neurology and GU/GI disorders to build a pipeline of clinical candidates.
Sold to Alcan in September 2009. ESBATech is a preclinical stage drug discovery company that intends to refocus the business to build a world class Ophthalmology company on the back of an attractive, proprietary antibody fragment platform which can deliver uniquely stable, soluble and monomeric fragments and compelling data on penetration of these fragments into the eye following topical treatment.Visit website
Eyetech was bought by OSI Pharmaceuticals after our exit through public markets. Opthalmolological drug development.
Sold to Merck in May 2006. GlycoFi was a production and engineering of therapeutics proteins.
Gyros, located in Uppsala, Sweden, has developed a proprietary microfluidics technology for processing and analysis of proteins and blood samples. Laboratory processes are integrated into a client specific disc (CD) format. The CD is processed and its contents analysed on software controlled instrumentation.Visit website
ITI is a specialty pharmaceutical company focused on developing innovative, nasally delivered pharmaceutical products with a particular focus on drugs treating pain and CNS-related disorders for which there is proven, unmet patient need.
Functional genomics Acquired by Incyte Pharmaceuticals in September 1999.
Ingenium was a functional genomics and drug development company.
Itero is an early stage company focused on the development and commercialization of differentiated biosimilar and second generation protein products that serve niche markets.
KuDOS was an oncology drug development company. Acquired by Astra Zeneca in December 2005.
LeukoSite was a treatment of Inflammatory diseases and cancer. Acquired by Amgen in October 1999.
Link Medicine is a clinical stage company spun out of Harvard University working on disease-modifying therapies for neurodegenerative diseases.
Lux is developing drugs for ophthalmic diseases. Their lead product is LX211, an oral drug for the treatment of uveitis.
Metris is a women's healthcare company that is developing drugs for the treatment of chronic gynecological and menstrual conditions.
Mpex based in San Diego, CA, is focused on the discovery and development of new-antibacterial drugs that meet the growing clinical need created by multi-drug resistant bacteria. Mpex has identified several approaches to increase the effectiveness of existing antibiotics and decrease the incidence of drug resistance to these antibiotics. Mpex's first product will be an inhaled antibiotic for serious lung infections.
Neurotech based in Lincoln, RI, has developed an encapsulated cell therapy for the delivery of therapeutic proteins in retinal diseases. The first product is ciliary neurothrophic factor (CNTF) for retinitis pigmentosa and age-related macular degeneration (geographic atrophy).Visit website
Oncoethix SA is a private Swiss company focused on developing a portfolio of three to five promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization.
Sold to Pfizer in October 2006. PowderMed developed therapeutic DNA vaccines in the areas of chronic viral diseases and cancer.
Quantum Dot developed nanocrystal biological reagents.
Sold to J&J in June 2010. RespiVert is a discovery company focused on Chronic obstructive pulmonary disease ('COPD') and severe asthma. The company's goal is to develop novel inhaled and intranasal drugs for respiratory disorders with high unmet medical need and high commercial potential based on novel insights on biology and chemistry.
Sold to Pfizer in April 2006. Rinat developed proteins for the treatment of diseases and disorders of the nervous system.
Acquired by Helsinn in February 2009. Helsinn is developing small molecule drugs based on the biology of ghrelin,a gut peptide known to stimulate appetite. The lead compound is in Ph II for cancer cachexia; a second compound has completed an initial clinical study and is moving toward Ph II for post-operative ileus. Additional indications are being explored for follow-on compounds. Formerly known as Rejuvenon.
Sold to Illumina ILMN. Solexa used ultra high throughput DNA sequencing.
Third Wave Technologies
Third Wave developed products for analysing genetic variations.
Trine, formerly Essential Therapeutics Inc., in-licenses, develops and plans to commercialize new classes of pharmaceutical products focused on renal, metabolic and GI clinical areas.
Versicor was a drug development company for infectious diseases (Changed name to Vicurion Pharmaceuticals in 2003)
X2-Pharma is a biopharmaceutical company dedicated to the discovery and development of small molecule pharmaceuticals for the treatment of inflammatory diseases.